Institutional shares held 159 Million
100K calls
26.8K puts
Total value of holdings $542M
$342K calls
$91K puts
Market Cap $410M
120,219,000 Shares Out.
Institutional ownership 132.21%
# of Institutions 207


Latest Institutional Activity in RLAY

Top Purchases

Q4 2024
Norges Bank Shares Held: 5.78M ($19.7M)
Q4 2024
Tang Capital Management LLC Shares Held: 8.07M ($27.5M)
Q4 2024
Millennium Management LLC Shares Held: 2.57M ($8.76M)
Q4 2024
Dimensional Fund Advisors LP Shares Held: 2.96M ($10.1M)
Q4 2024
Kynam Capital Management, LP Shares Held: 1M ($3.41M)

Top Sells

Q4 2024
Citadel Advisors LLC Shares Held: 687K ($2.34M)
Q4 2024
Price T Rowe Associates Inc Shares Held: 3.32M ($11.3M)
Q4 2024
Eco R1 Capital, LLC Shares Held: 641K ($2.19M)
Q4 2024
Marshall Wace, LLP Shares Held: 27.8K ($94.7K)
Q4 2024
Franklin Resources Inc Shares Held: 58.8K ($201K)

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at RLAY

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.06M Shares
From 7 Insiders
Grant, award, or other acquisition 931K shares
Exercise of conversion of derivative security 129K shares
Sell / Disposition
1.28M Shares
From 5 Insiders
Open market or private sale 1.28M shares

Track Institutional and Insider Activities on RLAY

Follow Relay Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RLAY shares.

Notify only if

Insider Trading

Get notified when an Relay Therapeutics, Inc. insider buys or sells RLAY shares.

Notify only if

News

Receive news related to Relay Therapeutics, Inc.

Track Activities on RLAY